Lindbrook Capital’s ANI Pharmaceuticals ANIP Stock Holding History

Lindbrook Capital’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$7.83K	Hold	117	–	–	﹤0.01%	1757
2024 Q4	$6.47K	Hold	117	–	–	﹤0.01%	1870
2024 Q3	$6.98K	Hold	117	–	–	﹤0.01%	1859
2024 Q2	$7.45K	Hold	117	–	–	﹤0.01%	1796
2024 Q1	$8.09K	Hold	117	–	–	﹤0.01%	1675
2023 Q4	$6.45K	Hold	117	–	–	﹤0.01%	1754
2023 Q3	$6.79K	Hold	117	–	–	﹤0.01%	1614
2023 Q2	$6.3K	Hold	117	–	–	﹤0.01%	1696
2023 Q1	$4.65K	Sell	117 -8	-6%	-$337	﹤0.01%	1877
2022 Q4	$5.03K	Hold	125	–	–	﹤0.01%	1823
2022 Q3	$4K	Hold	125	–	–	﹤0.01%	1727
2022 Q2	$4K	Buy	125 +15	+14%	+$433	﹤0.01%	1608
2022 Q1	$3K	Buy	+110	New	+$4.1K	﹤0.01%	1781
2019 Q3	–	Sell	-200	Closed	-$16K	–	1436
2019 Q2	$16K	Buy	+200	New	+$14.2K	0.01%	758

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Lindbrook Capital's ANIP Position: Q1 2025 in Review

Lindbrook Capital held its ANI Pharmaceuticals (ANIP) position steady in Q1 2025 at 117 shares worth $7.83K. The position accounts for ﹤0.01% of the portfolio, ranked #1757.

Lindbrook Capital first reported a position in ANIP in Q2 2019 and has held it in 14 quarters since. The position peaked at $16K in Q2 2019. 230 funds tracked by Wall St. Rank hold ANIP as of Q1 2025.

Lindbrook Capital held 117 shares of ANI Pharmaceuticals worth $7.83K as of Q1 2025.
Lindbrook Capital left its ANI Pharmaceuticals share count unchanged in Q1 2025.
ANI Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1757 holding.
Lindbrook Capital first reported a position in ANI Pharmaceuticals in Q2 2019 and has held it in 14 quarters since.
Lindbrook Capital's ANI Pharmaceuticals position peaked at $16K in Q2 2019.
230 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.